Patient clinical and laboratory characteristics
Variable . | All patients . | Seen at VUMC within 1 y of diagnosis . | Seen at VUMC after 1 y of diagnosis . | |||
|---|---|---|---|---|---|---|
| No. (%) . | . | No. (%) . | . | No. (%) . | . | |
| No. of patients | 193 | 158 | 35 | |||
| Median age | 59 | 59.5 | 56 | |||
| Range | (24-87) | (24-87) | (34-78) | |||
| Primary myelofibrosis | 156 (80.8) | |||||
| After polycythemia vera - myelofibrosis | 29 (15) | |||||
| After essential thrombocythemia - myelofibrosis | 26 (13.5) | |||||
| Female | 82 (42.5) | 66 (41.8) | 16 (45.7) | |||
| Median follow-up, y | 4 | (1-22) | 2.5 | (1-16) | 6 | (1-22) |
| Age >65 y | 63 (29.9) | 51 (32.3) | 12 (34.3) | |||
| Laboratory characteristics | ||||||
| Leukocytes, × 109/L | 193 | 158 | 35 | |||
| Median | 13.8 | 13 | 16.4 | |||
| Range | (0.8-256.3) | (0.8-256.3) | (1.7-179.6) | |||
| Leukocytes >25 ×109/L | 57 (29.5) | 42 (26.6) | 15 (29.5) | |||
| Hemoglobin, g/dL | 193 | 158 | 35 | |||
| Median | 9.3 | 8.95 | 9.9 | |||
| Range | (4.8-15.7) | (4.8-15.7) | (5.3-15.7) | |||
| Hemoglobin ≤10 g/dL | 109 (56.5) | 91 (57.6) | 18 (51.4) | |||
| Platelets, ×109/L | 193 | 158 | 35 | |||
| Median | 147 | 145 | 151 | |||
| Range | (5-1007) | (5-1007) | (8-712) | |||
| Platelets <100 ×109/L | 75 (38.9) | 61 (38.6) | 14 (40) | |||
| Platelets <200 ×109/L | 119 (61.7) | 98 (62) | 21 (60) | |||
| Circulating blasts | 110 (57) | 90 (57) | 20 (57.1) | |||
| Circulating blasts >1% | 83 (43) | 71 (44.9) | 12 (34.3) | |||
| Circulating blasts >2% | 66 (34.2) | 55 (34.8) | 11 (31.4) | |||
| Cytogenetics | 193 | 158 | 35 | |||
| High risk (DIPSS Plus definition) | 12 (6.2) | 9 (5.7) | 3 (8.6) | |||
| Very high risk (GPSS definition) | 10 (5.2) | 8 (5.1) | 2 (5.7) | |||
| High risk (GPSS definition) | 32 (16.6) | 26 (16.5) | 6 (17.1) | |||
| High risk (MIPSS70 Plus definition) | 22 (11.4) | 19 (12) | 3 (8.6) | |||
| Next-generation sequencing | 140 (72.5) | 112 (70.9) | 28 (80) | |||
| Mutation detected | 118 (84.3) | 96 (85.7) | 22 (78.6) | |||
| Driver mutation | ||||||
| JAK2WT, MPLWT, and CALRWT (triple negative) | 71 (50.7) | |||||
| JAK2V617F | 78 (55.7) | |||||
| CALR mutation | 16 (11.4) | |||||
| MPL mutation | 9 (6.4) | |||||
| High molecular risk | ||||||
| ASXL1 | 17 (12.1) | |||||
| EZH2 | 8 (5.7) | |||||
| SRSF2 | 15 (10.7) | |||||
| IDH1/2 | 3 (2.1) | |||||
| ≥2 High molecular risk (MIPSS 70+) | 8 (5.7) | |||||
| Outcomes | ||||||
| Allogeneic stem cell transplant | 40 (20.7) | 32 (20.3) | 8 (22.9) | |||
| Leukemic transformation | 23 (11.9) | 20 (12.7) | 10 (28.6) | |||
| Death | 42 (21.8) | 36 (22.8) | 6 (17.1) | |||
Variable . | All patients . | Seen at VUMC within 1 y of diagnosis . | Seen at VUMC after 1 y of diagnosis . | |||
|---|---|---|---|---|---|---|
| No. (%) . | . | No. (%) . | . | No. (%) . | . | |
| No. of patients | 193 | 158 | 35 | |||
| Median age | 59 | 59.5 | 56 | |||
| Range | (24-87) | (24-87) | (34-78) | |||
| Primary myelofibrosis | 156 (80.8) | |||||
| After polycythemia vera - myelofibrosis | 29 (15) | |||||
| After essential thrombocythemia - myelofibrosis | 26 (13.5) | |||||
| Female | 82 (42.5) | 66 (41.8) | 16 (45.7) | |||
| Median follow-up, y | 4 | (1-22) | 2.5 | (1-16) | 6 | (1-22) |
| Age >65 y | 63 (29.9) | 51 (32.3) | 12 (34.3) | |||
| Laboratory characteristics | ||||||
| Leukocytes, × 109/L | 193 | 158 | 35 | |||
| Median | 13.8 | 13 | 16.4 | |||
| Range | (0.8-256.3) | (0.8-256.3) | (1.7-179.6) | |||
| Leukocytes >25 ×109/L | 57 (29.5) | 42 (26.6) | 15 (29.5) | |||
| Hemoglobin, g/dL | 193 | 158 | 35 | |||
| Median | 9.3 | 8.95 | 9.9 | |||
| Range | (4.8-15.7) | (4.8-15.7) | (5.3-15.7) | |||
| Hemoglobin ≤10 g/dL | 109 (56.5) | 91 (57.6) | 18 (51.4) | |||
| Platelets, ×109/L | 193 | 158 | 35 | |||
| Median | 147 | 145 | 151 | |||
| Range | (5-1007) | (5-1007) | (8-712) | |||
| Platelets <100 ×109/L | 75 (38.9) | 61 (38.6) | 14 (40) | |||
| Platelets <200 ×109/L | 119 (61.7) | 98 (62) | 21 (60) | |||
| Circulating blasts | 110 (57) | 90 (57) | 20 (57.1) | |||
| Circulating blasts >1% | 83 (43) | 71 (44.9) | 12 (34.3) | |||
| Circulating blasts >2% | 66 (34.2) | 55 (34.8) | 11 (31.4) | |||
| Cytogenetics | 193 | 158 | 35 | |||
| High risk (DIPSS Plus definition) | 12 (6.2) | 9 (5.7) | 3 (8.6) | |||
| Very high risk (GPSS definition) | 10 (5.2) | 8 (5.1) | 2 (5.7) | |||
| High risk (GPSS definition) | 32 (16.6) | 26 (16.5) | 6 (17.1) | |||
| High risk (MIPSS70 Plus definition) | 22 (11.4) | 19 (12) | 3 (8.6) | |||
| Next-generation sequencing | 140 (72.5) | 112 (70.9) | 28 (80) | |||
| Mutation detected | 118 (84.3) | 96 (85.7) | 22 (78.6) | |||
| Driver mutation | ||||||
| JAK2WT, MPLWT, and CALRWT (triple negative) | 71 (50.7) | |||||
| JAK2V617F | 78 (55.7) | |||||
| CALR mutation | 16 (11.4) | |||||
| MPL mutation | 9 (6.4) | |||||
| High molecular risk | ||||||
| ASXL1 | 17 (12.1) | |||||
| EZH2 | 8 (5.7) | |||||
| SRSF2 | 15 (10.7) | |||||
| IDH1/2 | 3 (2.1) | |||||
| ≥2 High molecular risk (MIPSS 70+) | 8 (5.7) | |||||
| Outcomes | ||||||
| Allogeneic stem cell transplant | 40 (20.7) | 32 (20.3) | 8 (22.9) | |||
| Leukemic transformation | 23 (11.9) | 20 (12.7) | 10 (28.6) | |||
| Death | 42 (21.8) | 36 (22.8) | 6 (17.1) | |||
Patient clinical and laboratory characteristics stratified by time of referral and patient at Vanderbilt University (N = 193).
VUMC, Vanderbilt University Medical Center.